HRASV12 is a frequent oncogenic mutation in cancers, and expression in mouse melanocytes has been key to our understanding of how RAS signaling cooperates with mutations in the INK4A-RB or ARF-p53 pathways to promote melanoma (Chin et al., 2006). Here, CDKN2A is linked to cancer.